Freya Pharma Solutions Announces Advice from the FDA on its US Clinical Development Program of Lybrido for the treatment of Female Sexual Interest/Arousal Disorder

AMSTERDAM, May 9, 2023 /PRNewswire/ -- Freya Pharma Solutions, a pharmaceutical company focusing on the development of effective pharmaceutical therapies for women diagnosed with Female Sexual

Related Keywords

Amsterdam ,Noord Holland ,Netherlands ,United States ,American ,Marcel Wijma ,Us Clinical Development Program Of Lybrido ,European Medicines Agency ,Drug Administration ,American Psychiatric Association ,Freya Pharma Solutions ,Prnewswire Freya Pharma Solutions ,Lifespring Life Sciences Communication ,Pharma Solutions ,Female Sexual Disorders ,Development Program ,Female Sexual ,Arousal Disorder ,Scientific Advisory Board ,Marketing Authorization Application ,Chief Medical Officer ,Sexual Desire Disorder ,Statistical Manual ,Mental Disorders ,Chief Executive ,Spring Life Sciences Communication ,Gefallene Big Techs ,Freya ,Dharma ,Solutions ,Nnounces ,Advice ,Rom ,Linical ,Development ,Program ,Ybrido ,Treatment ,Female ,Isexual ,Interest ,Arousal ,Disorder ,